GRO Biosciences

GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.

A Change in Bacteria’s Genetic Code Holds Promise of Longer-Lasting Drugs

By altering the genetic code in bacteria, GRObio co-founders Ross Thyer and Andrew Ellington have demonstrated a method to make therapeutic proteins more stable, an advance that would improve the drugs' effectiveness and convenience, leading to smaller and less frequent doses of medicine, lower health care costs and fewer side effects for patients with cancer and other diseases.

Read More

Hacking the Biological Source Code: Our Investment in GRO Biosciences

Is it possible to take the essence of the code and reprogram it in a way nature had not intended? Today, we are excited to announce an investment in a group doing just that - GRO Biosciences (GRObio) - a deal we co-led with our friends at Digitalis. GRObio has solidified the transition from read to write; GRObio has hacked biology to create a highly modified organism with only 63, not 64, of those simple repeats called codons. By freeing a codon, GRObio has begun to define the art of the possible in synthetic biology.

Read More

GRO Biosciences Secures $2.1M in Seed Funding

GRO Biosciences Inc. today announced that the company has secured $2.1 million in a seed funding round co-led by Digitalis Ventures and Eric Schmidt’s Innovation Endeavors. The funds will support buildout of bioprocess development for GRO Biosciences’ platform of genomically recoded bacteria for the production of therapeutic proteins with enhanced properties, such as increased potency and stability, and improved targeting and delivery into cells and tissues.

Read More